Anteo Diagnostics: ASX Spotlight Presentation (Feb 2014)

Company Presentations

Anteo Diagnostics Limited (ASX:ADO) CEO Geoff Cumming presents at ASX Spotlight New York and London about the company’s operations in the life sciences sector.

Anteo's technology allows antibodies to be attached to solid objects to facilitate a new range of diagnostic tests. Interest from the US and Europe as well as the securing of numerous patents has Anteo in a position to grow in several global markets.

Anteo's game changing Mix&Go technology has given rise to an innovative range of products which are expected to make the company cashflow positive this financial year.

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.